DEA Pauses the Schedule III Hearing: What the GAO Report Means for Canadian Producers

For months, the US cannabis industry has been counting down to a decision that could reshape the market: whether the Drug Enforcement Administration (DEA) will move marijuana from Schedule I to Schedule III. On 29 September 2026, that countdown stopped. The DEA's chief administrative law judge paused the rescheduling hearing after opponents pointed to a new government report questioning how federal agencies make scheduling decisions in the first place.

For Canadian licensed producers watching the US market, this is more than American political theatre. The outcome affects whether and when a federally recognized US pathway opens, what tax treatment US operators will face, and how high the quality bar will be for anyone who wants to supply that market. This article updates our earlier coverage of the Schedule III process and explains what the pause means and what to do while the proceeding is on hold.

Executive Summary

On 29 September 2026, DEA Chief Administrative Law Judge Derek Julius stayed the marijuana rescheduling hearing after participants moved to admit a new Government Accountability Office (GAO) report into the record. The report, GAO-26-108623, found that both the DEA and the US Food and Drug Administration (FDA) lack comprehensive policies and procedures for how they evaluate and schedule controlled substances. It did not recommend any particular schedule for marijuana. The DEA and other parties have until 13 October 2026 to respond. The practical effect is delay and renewed uncertainty: a move to Schedule III would end the reach of tax code section 280E for marijuana businesses, while a move to Schedule II would not, and both remain on the table.

What Happened: The Hearing Is Stayed

What is it? A stay, or pause, of the DEA administrative hearing that was deciding whether to reschedule marijuana. Why it matters? It delays any US rescheduling and the tax relief that a Schedule III move would bring. What to do? Stop planning around a fixed date, and prepare for more than one outcome.

The expedited hearing on moving marijuana to Schedule III began in late June 2026. In late September, participants opposed to rescheduling asked the judge to admit the newly published GAO report into the record, arguing it showed the federal scheduling process was flawed. On 29 September 2026, Chief Administrative Law Judge Derek Julius granted a stay and set a deadline of 13 October 2026 for the DEA, and optionally other parties, to respond. Until the judge rules on how to proceed, the hearing does not move forward and marijuana remains in Schedule I.

Date (2026)	Event
Late June	Expedited DEA hearing on rescheduling marijuana to Schedule III begins
23 September	GAO publishes report GAO-26-108623 on scheduling process gaps at the DEA and FDA
28 September	Hearing participants move to admit the GAO report into the record
29 September	Chief Administrative Law Judge Derek Julius stays the proceeding
13 October	Deadline for the DEA and other parties to file responses (up to 20 pages)

What the GAO Report Actually Found

What is it? A GAO review of how the DEA and FDA run the controlled-substance scheduling process. Why it matters? It gave opponents a credible, nonpartisan basis to argue the process needs fixing before a decision lands. What to do? Read the findings for what they are: a process critique, not a verdict on marijuana.

The report, GAO-26-108623, published 23 September 2026, is titled Drug Scheduling: While DEA Decisions Have Aligned with Recent HHS Recommendations, Both Need Comprehensive Policies. GAO found that the DEA's final scheduling decisions aligned with Department of Health and Human Services recommendations in the cases it reviewed, but that the DEA does not have policies identifying the roles, responsibilities and procedures for scheduling, and that the FDA lacks policies specifying how its staff conduct evaluations. It also noted that a key interagency memorandum is more than 40 years old. Crucially, the report made no recommendation about whether marijuana should sit in Schedule I, II or III.

That distinction matters. Opponents used the report to argue the process is not rigorous enough to support a rescheduling decision right now. Supporters counter that process gaps do not change the scientific and medical evidence already on the record. The judge has not accepted either framing; the stay simply gives the parties time to respond.

Schedule III, Schedule II and the 280E Question

What is it? The tax and control consequences that flow from where marijuana lands on the federal schedule. Why it matters? The difference between Schedule II and Schedule III is the difference between no tax relief and a major one. What to do? Model both scenarios rather than assuming Schedule III is inevitable.

Section 280E of the US Internal Revenue Code (26 U.S.C. 280E) denies ordinary business deductions to any business trafficking in a Schedule I or Schedule II controlled substance. That is why US cannabis operators pay tax on gross profit rather than net income. Moving marijuana to Schedule III would remove it from the reach of 280E, freeing operators to deduct normal business expenses. A move to Schedule II would keep 280E in force and add heavy DEA registration and security requirements, offering control without the tax relief. Because the stay keeps both outcomes open, the financial modelling for anyone exposed to the US market has to cover more than one path.

Possible outcome	Effect on 280E	What it means for Canadian producers
Marijuana stays in Schedule I	280E continues to apply; no federal commercial pathway	US federal market stays closed; focus on Canada, the UK, the EU and other export markets
Rescheduled to Schedule II	280E still applies; strict DEA controls and registration	Limited practical relief; heavy security and registration burden and no tax benefit
Rescheduled to Schedule III	280E no longer applies to marijuana businesses	A federally recognized pathway opens; GMP-grade quality systems become a commercial differentiator

What the Pause Means for Canadian Producers

What is it? A delay in the US timeline that Canadian producers have been planning around. Why it matters? Export strategy, investment timing and quality investment all depend on that timeline. What to do? Keep building the quality foundation that any US pathway will demand, and do not let a Canadian compliance gap undercut it.

Nothing about this US proceeding changes Canadian law. Obligations under the Cannabis Act, the Cannabis Regulations and the Controlled Drugs and Substances Act continue as before. What changes is planning. A Schedule III move would reward producers whose quality systems already meet pharmaceutical expectations, which is why we have argued that a strong quality system is now a sales asset for Canadian LPs, not just a compliance cost. In the meantime, markets that are open today, such as the UK medical cannabis market, deserve attention while the US timeline stays uncertain.

The foundation stays the same on both sides of the border: disciplined records, validated processes, security and traceability. Producers should keep current with Canadian controlled-substance rules, including the new Controlled Substances Regulations (SOR/2025-242), and keep routine obligations such as annual regulatory fees and medical exemption declarations clean, because a weak domestic compliance record is the fastest way to lose credibility with a future US or export partner.

What a Schedule III Pathway Would Demand

What is it? The practical quality and regulatory bar a Schedule III world would set for anyone supplying the US market. Why it matters? That bar is high, and building to it takes time you only have while the decision is paused. What to do? Use the delay to close quality gaps rather than to wait.

Schedule III substances are prescription medicines. A marijuana Schedule III world would likely bring FDA oversight for products marketed with drug claims, DEA registration for those who handle the substance, and manufacturing to pharmaceutical good manufacturing practice. For Canadian producers, that shifts the quality conversation from cannabis good production practices to drug-grade expectations: EU-GMP or an equivalent standard, validated analytical methods, documented stability data, controlled supply chains, and a quality management system that can withstand a regulatory inspection. These are not features a producer can add in a week.

This is why the pause is not idle time. A dossier-grade quality system, validated methods and a credible stability programme take many months to build and prove. Producers who use the delay to close GMP gaps, qualify suppliers and document their quality data will be ready to move quickly if a pathway opens. Those who simply wait for a headline will start the real work from behind, at the exact moment speed matters most.

US Rescheduling Readiness Checklist

Use this checklist to stay ready whichever way the decision lands.

Stop planning around a fixed rescheduling date; treat the timeline as uncertain.
Track the 13 October 2026 response deadline and any further orders in the DEA proceeding.
Keep your quality management system export-ready and aligned with GMP expectations.
Document product quality, testing and stability data to pharmaceutical standards.
Model both Schedule II and Schedule III outcomes, including the 280E tax impact.
Maintain Canadian licence compliance, security clearances and traceability as the foundation.
Prepare DEA registration readiness materials in case a Schedule III pathway opens.
Monitor Federal Register and DEA Diversion Control updates for the next procedural step.

Common Mistakes

Treating rescheduling as imminent or certain. The stay shows how quickly the timeline can shift.
Assuming Schedule III is the only outcome. Schedule II, with no 280E relief, remains possible.
Neglecting quality systems while waiting. A weak quality system will not be export-ready when a window opens.
Confusing US rescheduling with Canadian legality. Canadian obligations under the Cannabis Act and controlled-substance rules do not change.
Ignoring the process-gap findings. The GAO report signals that future decisions may face more scrutiny and delay.

Frequently Asked Questions

What exactly did the DEA judge decide?

The Chief Administrative Law Judge stayed, or paused, the rescheduling proceeding on 29 September 2026 after participants raised the GAO report. The DEA and other parties have until 13 October to respond, after which the judge will decide how to proceed. The stay does not reschedule marijuana; it delays the hearing.

Did the GAO report say marijuana should be Schedule III?

No. GAO-26-108623 examined how the DEA and FDA run the scheduling process and found both lack comprehensive policies and procedures. It made no recommendation about marijuana's specific schedule.

What is 280E and why does it matter?

Section 280E of the US Internal Revenue Code denies ordinary business deductions to businesses trafficking in Schedule I or II controlled substances. Moving marijuana to Schedule III would end 280E's application to those businesses; a move to Schedule II would not.

How does this affect Canadian licensed producers?

Most directly, it delays any US federal commercial pathway and the tax relief a Schedule III move would bring. Canadian LPs eyeing the US should plan for a longer, less certain timeline and keep their quality systems export-ready.

Does this change anything under Canadian law?

No. Canadian obligations under the Cannabis Act, the Cannabis Regulations and the Controlled Drugs and Substances Act are unaffected by US scheduling decisions. This is a US proceeding.

What should we do while the proceeding is paused?

Watch the 13 October deadline and later orders, model both Schedule II and III scenarios, and invest in a GMP-aligned quality system so you are ready to move if a US pathway opens.

How MFLRC Can Help

MFLRC helps cannabis and controlled-substance businesses build the quality and regulatory foundation that export and market access depend on. For cannabis and hemp producers and controlled drug operators, that means GMP and GPP quality systems, QAP services, SOP development, audits and gap assessments, and regulatory affairs and import/export strategy for Canada, the US and other markets. We help you model rescheduling scenarios, prepare DEA registration readiness, and make sure your quality system is a differentiator rather than a liability when a market opens.

Planning for the US market while the rescheduling decision is on hold? Book a consultation with MFLRC and build an export-ready quality and regulatory strategy that works whichever way the decision lands.

Book a Consultation

Conclusion

The pause in the DEA rescheduling hearing is a reminder that regulatory timelines are promises, not guarantees. A single government report on process was enough to stop a long-awaited decision in its tracks. For Canadian producers, the lesson is not to wait and hope, but to build. The producers who will win when a US pathway finally opens are the ones who used the delay to strengthen their quality systems, tighten their records and keep their Canadian compliance spotless. Watch the 13 October deadline, plan for more than one outcome, and treat quality as the asset it is.